 |
| |
| May-07-20 | Downgrade |
Cantor Fitzgerald |
Overweight → Neutral |
|
|
| Sep-12-19 | Initiated |
Guggenheim |
Buy |
|
|
| May-10-19 | Downgrade |
Raymond James |
Strong Buy → Outperform |
$73 → $82 |
|
| Oct-16-17 | Reiterated |
Canaccord Genuity |
Buy |
$60 → $66 |
|
| Jul-31-17 | Initiated |
Canaccord Genuity |
Buy |
$60 |
|
| Feb-22-17 | Downgrade |
ROTH Capital |
Buy → Neutral |
|
|
| Jun-23-16 | Initiated |
Raymond James |
Strong Buy |
$68 |
|
| May-24-16 | Downgrade |
Standpoint Research |
Buy → Hold |
|
|
| Nov-13-15 | Initiated |
Standpoint Research |
Buy |
$54 |
|
| Sep-28-15 | Upgrade |
ROTH Capital |
Neutral → Buy |
$67 → $60 |
|
| Aug-05-15 | Reiterated |
Oppenheimer |
Outperform |
$74 → $65 |
|
| Aug-04-15 | Reiterated |
ROTH Capital |
Neutral |
$70 → $67 |
|
| Jul-31-15 | Reiterated |
Oppenheimer |
Outperform |
$72 → $74 |
|
| Jul-15-15 | Reiterated |
ROTH Capital |
Neutral |
$60 → $70 |
|
| Jun-23-15 | Reiterated |
Oppenheimer |
Outperform |
$61 → $67 |
|
| May-18-15 | Reiterated |
ROTH Capital |
Neutral |
$78 → $60 |
|
| May-06-15 | Reiterated |
Oppenheimer |
Outperform |
$69 → $61 |
|
| Apr-10-15 | Downgrade |
ROTH Capital |
Buy → Neutral |
$78 |
|
| Feb-26-15 | Reiterated |
ROTH Capital |
Buy |
$65 → $78 |
|
| Feb-18-15 | Reiterated |
Oppenheimer |
Outperform |
$58 → $69 |
|
|
|
| May-09-20 08:21AM | Earnings Release: Here's Why Analysts Cut Their ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Price Target To US$45.67 Simply Wall St. |
| May-08-20 06:30PM | ANI Pharmaceuticals Inc (ANIP) Q1 2020 Earnings Call Transcript Motley Fool |
| 07:12AM | Edited Transcript of ANIP earnings conference call or presentation 7-May-20 2:30pm GMT Thomson Reuters StreetEvents |
| May-07-20 09:55AM | ANI Pharmaceuticals (ANIP) Q1 Earnings and Revenues Surpass Estimates Zacks -7.85% |
| 08:30AM | ANI Pharmaceuticals Reports First Quarter 2020 Results and Appoints Interim CEO PR Newswire |
| May-01-20 11:50AM | Are Investors Undervaluing ANI Pharmaceuticals (ANIP) Right Now? Zacks |
| Apr-30-20 08:30AM | ANI Pharmaceuticals Schedules Conference Call to Discuss First Quarter 2020 Financial Results PR Newswire |
| Apr-29-20 08:30AM | ANI Receives Refusal to File Letter from FDA for Cortrophin® Gel PR Newswire -8.50% |
| Apr-24-20 06:45AM | The ANI Pharmaceuticals (NASDAQ:ANIP) Share Price Is Down 40% So Some Shareholders Are Getting Worried Simply Wall St. |
| Apr-14-20 08:30AM | ANI Announces Upcoming Departure of CEO PR Newswire -8.98% |
| Apr-13-20 08:30AM | ANI Announces FDA Acceptance of Supplemental Filing for Cortrophin® Gel 80 U/mL PR Newswire +6.12% |
| Apr-02-20 08:30AM | ANI Pharmaceuticals Announces Launch of Omega-3-Acid Ethyl Esters Capsules USP PR Newswire |
| Mar-26-20 08:30AM | ANI Announces Launch of Polyethylene Glycol 3350, 17g/Packet PR Newswire |
| Mar-24-20 08:30AM | ANI Pharmaceuticals Announces the Filing of a Prior Approval Supplement for Purified Cortrophin® Gel 80 U/mL PR Newswire +24.22% |
| Mar-11-20 03:37PM | Edited Transcript of ANIP earnings conference call or presentation 27-Feb-20 3:30pm GMT Thomson Reuters StreetEvents |
| Mar-10-20 06:40AM | A Sliding Share Price Has Us Looking At ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) P/E Ratio Simply Wall St. |
| Mar-05-20 07:17AM | New Strong Sell Stocks for March 5th Zacks -7.34% |
| Mar-02-20 08:30AM | ANI Pharmaceuticals Announces FDA Approval of Memantine Hydrochloride Extended-Release Capsules PR Newswire -7.81% |
| Feb-29-20 07:35AM | Earnings Miss: ANI Pharmaceuticals, Inc. Missed EPS By 53% And Analysts Are Revising Their Forecasts Simply Wall St. |
| Feb-27-20 10:05AM | ANI Pharmaceuticals (ANIP) Q4 Earnings and Revenues Lag Estimates Zacks -18.68% |
| 08:30AM | ANI Pharmaceuticals Reports Full Year and Fourth Quarter 2019 Results, Provides 2020 Guidance and Remains on Track to Submit Cortrophin® Gel sNDA to FDA in March 2020 PR Newswire |
| Feb-24-20 12:45PM | 3 Fast-Growing CapEx Stocks GuruFocus.com |
| Feb-21-20 05:25AM | Read This Before Judging ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) ROE Simply Wall St. |
| Feb-20-20 08:30AM | ANI Pharmaceuticals Schedules Conference Call to Discuss Fourth Quarter and Year-to-Date 2019 Financial Results PR Newswire |
| Feb-19-20 12:31PM | Earnings Preview: ANI Pharmaceuticals (ANIP) Q4 Earnings Expected to Decline Zacks |
| Feb-12-20 08:30AM | ANI Announces Launch of Sulfamethoxazole and Trimethoprim Oral Suspension USP 200 mg/40 mg per 5 mL PR Newswire |
| Jan-24-20 08:30AM | ANI Announces Launch of Tolterodine Extended-Release Capsules PR Newswire |
| Jan-16-20 08:30AM | ANI Pharmaceuticals Announces FDA Approval of Potassium Citrate Extended-Release Tablets USP PR Newswire |
| 05:39AM | Is ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) CEO Pay Justified? Simply Wall St. |
| Jan-14-20 08:30AM | ANI Announces Launch of Paliperidone Extended-Release Tablets PR Newswire |
| Jan-09-20 08:30AM | ANI Pharmaceuticals Announces Acquisition of Commercial and Pipeline Generic Products from Amerigen Pharmaceuticals, Ltd. PR Newswire |
| Dec-19-19 10:09AM | 4 Drug/Biotech Outperformers That May Lose Steam in 2020 Zacks |
| Dec-18-19 08:30AM | ANI Pharmaceuticals Announces Launch of Bretylium Tosylate Injection, USP 50 mg/mL PR Newswire |
| Dec-11-19 01:55PM | Is ANI Pharmaceuticals Inc (ANIP) Going To Burn These Hedge Funds ? Insider Monkey |
| 05:06AM | Before You Buy ANI Pharmaceuticals, Inc. (NASDAQ:ANIP), Consider Its Volatility Simply Wall St. |
| Dec-04-19 09:21AM | New Strong Sell Stocks for December 4th Zacks |
| 07:45AM | Moving Average Crossover Alert: ANI Pharmaceuticals Zacks |
| Nov-26-19 08:30AM | ANI Pharmaceuticals to Present at Evercore ISI 2nd Annual HealthCONx Conference PR Newswire |
| Nov-22-19 05:19PM | Edited Transcript of ANIP earnings conference call or presentation 6-Nov-19 3:30pm GMT Thomson Reuters StreetEvents |
| Nov-11-19 06:25AM | Estimating The Intrinsic Value Of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Simply Wall St. |
| Nov-06-19 09:55AM | ANI Pharmaceuticals (ANIP) Lags Q3 Earnings and Revenue Estimates Zacks -23.75% |
| 08:30AM | ANI Pharmaceuticals Reports Third Quarter Results PR Newswire |
| 08:21AM | The Daily Biotech Pulse: Sesen Rallies On Positive FDA Meeting, Supernus Flunks Late-Stage ADHD Trial, GW Pharma Earnings Benzinga |
| Oct-31-19 08:30AM | ANI Announces Plans to Launch Bretylium Tosylate Injection, USP 500mg/10ml (50mg/ml) for Ventricular Arrhythmias PR Newswire |
| Oct-30-19 08:30AM | ANI Pharmaceuticals Schedules Conference Call to Discuss Third Quarter and Year-to-Date 2019 Financial Results PR Newswire |
| Oct-29-19 10:33AM | ANI Pharmaceuticals (ANIP) to Report Q3 Results: Wall Street Expects Earnings Growth Zacks |
| 08:30AM | ANI Pharmaceuticals announces the launch of ANI Global Source, its contract development and manufacturing business PR Newswire |
| Oct-28-19 04:14PM | Here is What Hedge Funds Think About ANI Pharmaceuticals Inc (ANIP) Insider Monkey |
| Oct-12-19 08:26AM | Does ANI Pharmaceuticals (NASDAQ:ANIP) Deserve A Spot On Your Watchlist? Simply Wall St. |
| Oct-11-19 12:18PM | Zacks.com featured highlights include: Assurant, Opera, ANI, eXp and Avista Zacks |
| Oct-10-19 10:37AM | Zacks.com featured highlights include: Assurant, Opera, ANI, eXp and Avista Zacks |
| Oct-09-19 09:09AM | 5 Stocks to Consider as New Analysts Initiate Coverage Zacks |
| Oct-03-19 08:30AM | ANI Announces Positive Clinical Results from Cortrophin® Gel Cortisol Response Study PR Newswire |
| Oct-02-19 08:30AM | ANI Pharmaceuticals Announces Launch of Aspirin and Extended Release Dipyridamole Capsules, 25mg/200mg PR Newswire |
| Sep-29-19 11:39AM | Hedge Fund Mangrove Partners Top Stock Picks Insider Monkey |
| Sep-12-19 06:57AM | ANI Pharmaceuticals (NASDAQ:ANIP) Takes On Some Risk With Its Use Of Debt Simply Wall St. |
| Sep-11-19 08:30AM | ANI Pharmaceuticals Announces Launch of Vancomycin Hydrochloride for Oral Solution USP, 250mg/5mL PR Newswire |
| Sep-05-19 06:43PM | Edited Transcript of ANIP earnings conference call or presentation 7-Aug-19 2:30pm GMT Thomson Reuters StreetEvents |
| Aug-13-19 08:08AM | ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Delivered A Weaker ROE Than Its Industry Simply Wall St. |
| Aug-07-19 01:23PM | ANI Pharmaceuticals Inc (ANIP) Q2 2019 Earnings Call Transcript Motley Fool -12.04% |
| 09:45AM | ANI Pharmaceuticals (ANIP) Q2 Earnings Surpass Estimates Zacks |
| 08:30AM | ANI Pharmaceuticals Reports Second Quarter Results PR Newswire |
| Jul-31-19 08:30AM | ANI Pharmaceuticals Schedules Conference Call to Discuss Second Quarter and Year-to-Date 2019 Financial Results PR Newswire |
| Jul-30-19 10:38AM | ANI Pharmaceuticals (ANIP) Earnings Expected to Grow: What to Know Ahead of Q2 Release Zacks |
| Jul-09-19 02:38PM | How Much is ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) CEO Getting Paid? Simply Wall St. |
| Jun-27-19 04:11PM | Hedge Funds Piled Into This Stock Right Before Its Double Digit Gains Insider Monkey |
| Jun-25-19 08:30AM | ANI Pharmaceuticals Announces Launch of Ranitidine Capsules PR Newswire |
| Jun-20-19 10:30AM | ANI Pharmaceuticals Announces Approval of Vancomycin Hydrochloride for Oral Solution USP, 250mg/5ml PR Newswire |
| Jun-18-19 08:00AM | ANI Pharmaceuticals Expands Generic Pipeline with Acquisition of Seven Development Stage Drug Products from Coeptis Pharmaceuticals, Inc. PR Newswire |
| Jun-12-19 08:30AM | ANI Pharmaceuticals to Present at Raymond James Life Sciences and MedTech Conference PR Newswire |
| May-31-19 12:38PM | Is ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Trading At A 48% Discount? Simply Wall St. |
| May-16-19 09:00AM | What Makes ANI (ANIP) a New Buy Stock Zacks |
| May-12-19 11:52AM | Edited Transcript of ANIP earnings conference call or presentation 9-May-19 2:30pm GMT Thomson Reuters StreetEvents |
| May-10-19 10:23AM | ANI Pharmaceuticals Inc (ANIP) Q1 2019 Earnings Call Transcript Motley Fool |
| May-09-19 01:14PM | Did Hedge Funds Drop The Ball On ANI Pharmaceuticals Inc (ANIP) ? Insider Monkey |
| 08:39AM | ANI: 1Q Earnings Snapshot Associated Press |
| 08:30AM | ANI Pharmaceuticals Reports First Quarter 2019 Results and Reaffirms Guidance PR Newswire |
| May-02-19 08:30AM | ANI Pharmaceuticals Schedules Conference Call to Discuss First Quarter 2019 Financial Results PR Newswire |
| May-01-19 05:45PM | ANI Pharmaceuticals (ANIP) Dips More Than Broader Markets: What You Should Know Zacks |
| Apr-30-19 09:00AM | The Zacks Analyst Blog Highlights: Bed Bath & Beyond, ANI, DXP, Foot Locker and ACI Zacks |
| 08:32AM | What's in Store for ANI Pharmaceuticals (ANIP) Q1 Earnings? Zacks |
| Apr-29-19 08:05AM | American Economy Hits the Gas: 5 Top Gainers Zacks |
| Apr-27-19 09:04AM | If You Had Bought ANI Pharmaceuticals (NASDAQ:ANIP) Shares Five Years Ago You'd Have Made 115% Simply Wall St. |
| Apr-26-19 11:11AM | Medicines Company (MDCO) Q1 Loss Narrows, Inclisiran in Focus Zacks |
| Apr-25-19 05:45PM | ANI Pharmaceuticals (ANIP) Dips More Than Broader Markets: What You Should Know Zacks |
| 09:31AM | Alexion (ALXN) Q1 Earnings Beat Estimates, Guidance Raised Zacks |
| Apr-23-19 09:34AM | Zacks.com featured expert Kevin Matras highlights: Advanced Emissions Solutions, Verint Systems, Great Lakes Dredge & Dock, ANI Pharmaceuticals and ACI Worldwide Zacks |
| Apr-22-19 09:12AM | 5 Stocks With Recent Price Strength to Enhance Your Returns Zacks |
| Apr-18-19 05:50PM | ANI Pharmaceuticals (ANIP) Stock Sinks As Market Gains: What You Should Know Zacks |
| Apr-17-19 08:14AM | Ultragenyx's (RARE) UX007 Gets Fast Track Status by FDA Zacks |
| Apr-16-19 10:54AM | QIAGEN Drives Molecular Diagnostics Suite With New Test Kit Zacks |
| Apr-15-19 09:30AM | Has ANI Pharmaceuticals (ANIP) Outpaced Other Medical Stocks This Year? Zacks |
| 08:45AM | 3 Reasons Why Growth Investors Shouldn't Overlook ANI (ANIP) Zacks |
| 08:30AM | ANI Pharmaceuticals Expands Injectable Portfolio with Distribution Agreement for FDA Approved Injectable Product PR Newswire |
| Apr-12-19 05:45PM | ANI Pharmaceuticals (ANIP) Outpaces Stock Market Gains: What You Should Know Zacks |
| 09:46AM | 5 Stocks With Increasing Cash Flows to Scoop Up Big Gains Zacks |
| Apr-11-19 10:43AM | Zacks.com featured expert Kevin Matras highlights: Herc, ANI Pharmaceuticals, Kamada, SP Plus and SkyWest Zacks |
| 09:34AM | BioDelivery (BDSI) Buys US Rights to Pain Drug for $30M Zacks |
| Apr-10-19 09:30AM | Tap These 6 Stocks That Flaunt Sizeable Net Profit Margin Zacks |
| Apr-09-19 11:24AM | PhaseBio Stock Up on Breakthrough Therapy Status for PB2452 Zacks |
|
|
|
|
| ANI Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncolytics (anti-cancers), hormones and steroids, and other formulations. The company offers pharmaceuticals for the treatment of breast cancer, hypertension, ventricular arrhythmias, stage D2 metastatic carcinoma of the prostate, depression, diarrhea, infections, vasomotor symptoms of menopause, pain caused by osteoarthritis and rheumatoid arthritis, epilepsy, arrhythmia, obsessive-compulsive disorder and social anxiety disorder, ulcerative colitis, salt and fluid retention, manic episodes of bipolar disorder, ulcerative colitis, proctosigmoiditis, ocular conditions, metastatic prostate cancer, arrhythmia, migraine headache, and enterocolitis caused by staphylococcus aureus. It also provides aspirin and extended-release dipyridamole; Cholestyramine, an adjunctive therapy to diet for the reduction of elevated serum cholesterol; Ezetimibe-Simvastatin to lower high cholesterol and triglyceride levels; Fenofibrate, a peroxisome proliferator receptor alpha activator; Hydrocortisone rectal cream for the relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses; Morphine Sulfate, an oral solution for acute and chronic pain management; Nimodipine to enhance neurological outcomes; and Terbutaline Sulfate for the prevention and reversal of bronchospasm. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract manufacturing for other pharmaceutical companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was founded in 2001 and is headquartered in Baudette, Minnesota. |
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| HAUGHEY THOMAS | Director | Mar 04 | Buy | 45.05 | 3,000 | 135,150 | 11,291 | Mar 05 06:01 PM | | HAUGHEY THOMAS | Director | Mar 03 | Buy | 45.18 | 2,000 | 90,360 | 8,291 | Mar 05 06:01 PM | | MERIDIAN VENTURE PARTNERS II L | 10% Owner | Aug 20 | Sale | 68.18 | 5,512 | 375,808 | 2,219,259 | Aug 21 06:11 PM | | MERIDIAN VENTURE PARTNERS II L | 10% Owner | Aug 19 | Sale | 68.30 | 2,067 | 141,176 | 2,224,771 | Aug 21 06:11 PM | | MERIDIAN VENTURE PARTNERS II L | 10% Owner | Aug 16 | Sale | 68.09 | 26,349 | 1,794,103 | 2,226,838 | Aug 16 05:38 PM | | MERIDIAN VENTURE PARTNERS II L | 10% Owner | Aug 15 | Sale | 69.34 | 9,315 | 645,902 | 2,253,187 | Aug 16 05:38 PM | | MERIDIAN VENTURE PARTNERS II L | 10% Owner | Aug 14 | Sale | 69.89 | 26,360 | 1,842,300 | 2,262,502 | Aug 16 05:38 PM | | MERIDIAN VENTURE PARTNERS II L | 10% Owner | Aug 13 | Sale | 71.77 | 20,821 | 1,494,323 | 2,288,862 | Aug 13 06:07 PM | | MERIDIAN VENTURE PARTNERS II L | 10% Owner | Aug 12 | Sale | 71.45 | 21,016 | 1,501,593 | 2,309,683 | Aug 13 06:07 PM | | MERIDIAN VENTURE PARTNERS II L | 10% Owner | Aug 09 | Sale | 71.70 | 19,860 | 1,423,962 | 2,330,699 | Aug 13 06:07 PM |
|
|
|
|
|
|
